AIM: Glycoprotein A repetitions predominant (GARP or LRRC32) represents a human regulatory CD4+ CD25(hi) FOXP3+ T (T(reg)) cell-specific receptor that controls FOXP3. Ectopic expression of GARP in helper T (T(h)) cells has been shown to be sufficient for the induction of FOXP3 and generation of a stable regulatory phenotype. Since expression of FOXP3 in Treg cells is epigenetically controlled by a conserved motif, the so-called T(reg)-specific demethylated region (TSDR), we asked whether GARP-mediated upregulation of FOXP3 in Th cells is similarly accompanied by demethylation of the TSDR. METHODS: DNA methylation of the FOXP3 TSDR was analyzed by direct sequencing of polymerase chain reaction (PCR) products from bisulfite-treated genomic DNA. RESULTS: Although GARP-transduced T(h) cells exhibit constitutive FOXP3 expression and a regulatory phenotype, the FOXP3 TSDR is completely methylated as in naive T(h) cells. GARP-mediated FOXP3 upregulation in T(h) cells is not associated with T(reg)-specific demethylation of the FOXP3 TSDR. CONCLUSION: Although GARP-engineered T(h) cells exhibit stable FOXP3 expression and a phenotypic reprogramming towards T(reg) cells in vitro, these cells do not completely mimic the epigenotype of natural T(reg) cells. Thus, concepts based on the genetic modification of T(h) cells as cellular therapies to treat autoimmune diseases or to control transplantation tolerance should be critically tested before any clinical application.
AIM: Glycoprotein A repetitions predominant (GARP or LRRC32) represents a human regulatory CD4+ CD25(hi) FOXP3+ T (T(reg)) cell-specific receptor that controls FOXP3. Ectopic expression of GARP in helper T (T(h)) cells has been shown to be sufficient for the induction of FOXP3 and generation of a stable regulatory phenotype. Since expression of FOXP3 in Treg cells is epigenetically controlled by a conserved motif, the so-called T(reg)-specific demethylated region (TSDR), we asked whether GARP-mediated upregulation of FOXP3 in Th cells is similarly accompanied by demethylation of the TSDR. METHODS: DNA methylation of the FOXP3 TSDR was analyzed by direct sequencing of polymerase chain reaction (PCR) products from bisulfite-treated genomic DNA. RESULTS: Although GARP-transduced T(h) cells exhibit constitutive FOXP3 expression and a regulatory phenotype, the FOXP3 TSDR is completely methylated as in naive T(h) cells. GARP-mediated FOXP3 upregulation in T(h) cells is not associated with T(reg)-specific demethylation of the FOXP3 TSDR. CONCLUSION: Although GARP-engineered T(h) cells exhibit stable FOXP3 expression and a phenotypic reprogramming towards T(reg) cells in vitro, these cells do not completely mimic the epigenotype of natural T(reg) cells. Thus, concepts based on the genetic modification of T(h) cells as cellular therapies to treat autoimmune diseases or to control transplantation tolerance should be critically tested before any clinical application.
Authors: Simone Reinwald; Carsten Wiethe; Astrid M Westendorf; Minka Breloer; Michael Probst-Kepper; Bernhard Fleischer; Alexander Steinkasserer; Jan Buer; Wiebke Hansen Journal: J Immunol Date: 2008-05-01 Impact factor: 5.422
Authors: Violaine François; Sabrina Ottaviani; Nicolina Renkvist; Julie Stockis; Gerold Schuler; Kris Thielemans; Didier Colau; Marie Marchand; Thierry Boon; Sophie Lucas; Pierre van der Bruggen Journal: Cancer Res Date: 2009-05-12 Impact factor: 12.701
Authors: Udo Baron; Stefan Floess; Georg Wieczorek; Katrin Baumann; Andreas Grützkau; Jun Dong; Andreas Thiel; Tina J Boeld; Petra Hoffmann; Matthias Edinger; Ivana Türbachova; Alf Hamann; Sven Olek; Jochen Huehn Journal: Eur J Immunol Date: 2007-09 Impact factor: 5.532
Authors: Jing Liu; Anna Lluis; Sabina Illi; Laura Layland; Sven Olek; Erika von Mutius; Bianca Schaub Journal: PLoS One Date: 2010-10-12 Impact factor: 3.240
Authors: Susanne Pfoertner; Andreas Jeron; Michael Probst-Kepper; Carlos A Guzman; Wiebke Hansen; Astrid M Westendorf; Tanja Toepfer; Andres J Schrader; Anke Franzke; Jan Buer; Robert Geffers Journal: Genome Biol Date: 2006 Impact factor: 13.583
Authors: M-H Haddadi; B Negahdari; E Hajizadeh-Saffar; M Khosravi-Maharlooei; M Basiri; H Dabiri; H Baharvand Journal: Clin Exp Immunol Date: 2020-06-08 Impact factor: 4.330
Authors: Jan Kehrmann; Roman Tatura; Michael Zeschnigk; Michael Probst-Kepper; Robert Geffers; Joerg Steinmann; Jan Buer Journal: Immunology Date: 2014-07 Impact factor: 7.397